Salvage treatment of recurrent, lymph node-positive prostate cancer in the modern era

The advent of imaging tests like the [11C]choline PET/CT scan and others have made it possible to identify, relatively early, the presence of one or more foci of recurrent prostate cancer after first-line therapy, and often these recurrent foci can be found in patients’ pelvic lymph nodes. … READ MORE …

A clear limit to the utility of [11C]choline PET/CT scanning

 A recently reported study by a group of German researchers has indicated that [11C]choline PET/CT scanning is not sufficently accurate to be able to identify, localize, and target areas of cancerous tissue within the prostate of a man known to have prostate cancer. … READ MORE …

FDA approves specialized imaging agent for PET scans in recurrent prostate cancer

The  U.S. Food & Drug Administration (FDA), yesterday, approved an imaging agent known as Choline C11 Injection for “production and use” to detect recurrent prostate cancer in men receiving positron emission tomongraphy or PET scanning. … READ MORE …